# US 2022/0009939 A1 · Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009939 A1
- Document ID: US20220009939A1
- Status: Published application
- Kind: A1
- Application number: 17/484,025
- Filed: 2021-09-24
- Published: 2022-01-13
- Earliest claimed: 2017-08-11
- Assignees: Actuate Therapeutics Inc.
- Applicants: Actuate Therapeutics Inc.
- Inventors: Yamin ZHANG
- Web page: https://patentgrep.com/patent/US20220009939A1

## CPC

- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 498/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A solid form of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, wherein said solid form is:
Solvate 1, characterized by an XRPD pattern comprising two, three, four, five, or six peaks selected from 7.2, 11.0, 14.6, 14.8, 15.6, and 22.3±0.2 degrees 2-theta;
Solvate 2, characterized by an XRPD pattern comprising two, three, four, five, six, seven, or eight peaks selected from 7.3, 8.0, 9.1, 10.1, 19.1, 19.3, 21.3, and 24.2±0.2 degrees 2-theta;
Solvate 3, characterized by an XRPD pattern comprising two, three, four, five, six, seven, or eight peaks selected from 8.0, 14.6, 16.2, 16.3, 21.7, 23.0, 24.3, and 25.9±0.2 degrees 2-theta;
Solvate 4, characterized by an XRPD pattern comprising two, three, four, five, six, or seven peaks selected from 9.8, 10.1, 10.9, 17.3, 20.9, 21.2, and 22.6±0.2 degrees 2-theta;
Solvate 5, characterized by an XRPD pattern comprising two, three, four, five, or six peaks selected from 5.4, 8.1, 14.8, 16.3, 21.6, and 24.0±0.2 degrees 2-theta;
Solvate 6, characterized by an XRPD pattern comprising two, three, four, or five peaks selected from 8.3, 14.7, 16.7, 22.2, and 24.6 degrees±0.2 degrees 2-theta;
Solvate 7, characterized by an XRPD pattern comprising two, three, or four peaks selected from 8.2, 16.5, 24.6, and 24.8 degrees±0.2 degrees 2-theta;
Solvate 8, characterized by an XRPD pattern comprising two, three, four, five, six, seven, eight, nine, or ten peaks selected from 6.2, 11.5, 12.5, 12.9, 15.0, 16.6, 18.8, 21.8, 25.2, and 27.2±0.2 degrees 2-theta; or
Solvate 9, characterized by an XRPD pattern comprising two, three, four, five, or six peaks selected from 7.2, 14.5, 15.7, 19.0, 22.4, 25.2, and 26.2±0.2 degrees 2-theta.

### Claim 27 (depends on 26)

A pharmaceutical composition comprising a solid form of claim 26 and a pharmaceutically acceptable excipient.

### Claim 28 (depends on 26)

A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a solid form of claim 26.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer is brain, lung, breast, ovarian, bladder, neuroblastoma, renal, or pancreatic cancer.

### Claim 30 (depends on 26)

A method of treating traumatic brain injury in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the solid form of claim 26.

### Claim 31

A solid form of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, which is amorphous.

### Claim 32 (depends on 31)

A pharmaceutical composition comprising a solid form of claim 31 and a pharmaceutically acceptable excipient.

### Claim 33 (depends on 31)

A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a solid form of claim 31.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cancer is brain, lung, breast, ovarian, bladder, neuroblastoma, renal, or pancreatic cancer.

### Claim 35 (depends on 31)

A method of treating traumatic brain injury in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the solid form of claim 31.
